Robert Milenkovski

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
AIMS Acute lymphoblastic leukemia (ALL) is an aggressive form of leukemia with a poor prognosis in adult patients. The addition of the monoclonal antibody rituximab to standard chemotherapy has been shown to improve survival in adults with ALL. However, it is unknown whether the addition of rituximab is cost-effective. The objective was to determine the(More)
  • 1